DK3257943T3 - Fremgangsmåder og vektorer til celleimmortalisering - Google Patents
Fremgangsmåder og vektorer til celleimmortaliseringInfo
- Publication number
- DK3257943T3 DK3257943T3 DK17180843.9T DK17180843T DK3257943T3 DK 3257943 T3 DK3257943 T3 DK 3257943T3 DK 17180843 T DK17180843 T DK 17180843T DK 3257943 T3 DK3257943 T3 DK 3257943T3
- Authority
- DK
- Denmark
- Prior art keywords
- vectors
- methods
- cell immortalization
- immortalization
- cell
- Prior art date
Links
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40950310P | 2010-11-02 | 2010-11-02 | |
| EP10014200 | 2010-11-02 | ||
| EP11778807.5A EP2635682B1 (en) | 2010-11-02 | 2011-11-02 | Methods and vectors for cell immortalisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3257943T3 true DK3257943T3 (da) | 2019-10-21 |
Family
ID=43513965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17180843.9T DK3257943T3 (da) | 2010-11-02 | 2011-11-02 | Fremgangsmåder og vektorer til celleimmortalisering |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9453203B2 (da) |
| EP (2) | EP3257943B1 (da) |
| JP (2) | JP6147191B2 (da) |
| CN (1) | CN103282498A (da) |
| AU (1) | AU2011325439B2 (da) |
| CA (1) | CA2814704C (da) |
| DK (1) | DK3257943T3 (da) |
| WO (1) | WO2012059223A1 (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3257943T3 (da) * | 2010-11-02 | 2019-10-21 | Helmholtz Zentrum Infektionsforschung Gmbh | Fremgangsmåder og vektorer til celleimmortalisering |
| WO2014109696A1 (en) * | 2013-01-10 | 2014-07-17 | Alf Grandien | Method for immortalization of b cells and uses thereof |
| CN104630136B (zh) * | 2013-11-15 | 2019-10-01 | 中国科学院广州生物医药与健康研究院 | 一种制备诱导多能性干细胞的方法以及该方法中所使用的组合物及其应用 |
| CN105960455B (zh) * | 2013-11-27 | 2020-02-04 | 株式会社钟化 | 细胞培养基及使用其的培养方法 |
| SG11201606934SA (en) * | 2014-03-04 | 2016-09-29 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
| KR102334203B1 (ko) * | 2017-08-09 | 2021-12-02 | 가부시키가이샤 만다무 | 불사화(不死化) 땀샘 근상피 세포 |
| CN119033819A (zh) | 2017-11-22 | 2024-11-29 | 迈索布拉斯特国际有限公司 | 细胞组合物及治疗方法 |
| CN109097335B (zh) * | 2018-08-29 | 2022-08-19 | 刘卫辉 | 正常肝干细胞向肝癌干细胞恶性转化的诱导方法 |
| CN109486769A (zh) * | 2018-10-16 | 2019-03-19 | 山东农业大学 | 一种对prrsv易感的猪子宫内膜上皮细胞系及其构建方法 |
| BR112022001912A2 (pt) | 2019-08-05 | 2022-04-19 | Mesoblast Int Sarl | Composições celulares compreendendo vetores virais e métodos de tratamento |
| WO2021060467A1 (ja) * | 2019-09-25 | 2021-04-01 | 国立大学法人東京大学 | 巨核球前駆細胞および巨核球細胞の製造方法並びに得られた巨核球前駆細胞および巨核球細胞 |
| JP7659784B2 (ja) * | 2019-10-17 | 2025-04-10 | 国立大学法人千葉大学 | 巨核球前駆細胞又は巨核球細胞の製造方法 |
| WO2021090594A1 (ja) * | 2019-11-04 | 2021-05-14 | 国立大学法人 東京大学 | 好中球前駆細胞及びその製造方法 |
| CN110699326A (zh) * | 2019-11-04 | 2020-01-17 | 郭津生 | 一种永生化人肝星状细胞株及其制备方法 |
| CN111154807B (zh) * | 2020-01-17 | 2023-03-24 | 山东农业大学 | 一种分泌型的崂山奶山羊乳腺上皮细胞系的构建方法 |
| JP6989859B2 (ja) * | 2020-04-10 | 2022-01-12 | 有限会社バラエティーエム・ワン | 情報コード、情報コード生成装置、情報コード読取装置、プログラムおよび情報コード利用システム |
| WO2022034506A1 (en) | 2020-08-10 | 2022-02-17 | Mesoblast International Sárl | Cellular compositions and methods of treatment |
| CN112574946B (zh) * | 2020-12-28 | 2023-12-12 | 中国科学院昆明动物研究所 | 一种原代分离培养土狗多个组织来源的成纤维细胞及其永生化的构建方法 |
| JP7670269B2 (ja) * | 2021-01-14 | 2025-04-30 | 学校法人日本医科大学 | 不死化間葉系細胞を含む細胞集団を製造する方法及び不死化間葉系細胞を含む細胞集団 |
| JP2024508797A (ja) * | 2021-02-22 | 2024-02-28 | ヴィトロラブズ インコーポレイテッド | 人工合成皮革のための不死化細胞株 |
| CN118176292A (zh) * | 2021-10-14 | 2024-06-11 | 北京干细胞与再生医学研究院 | 年轻化非多能性细胞及其制备方法和应用 |
| WO2023090901A1 (ko) * | 2021-11-18 | 2023-05-25 | 의료법인 성광의료재단 | 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법 |
| WO2023096380A1 (ko) * | 2021-11-26 | 2023-06-01 | 한양대학교 산학협력단 | 유전자 과발현을 이용해 조건부 성숙이 가능한 적혈구 전구세포주 확립 |
| CN114525238A (zh) * | 2022-02-14 | 2022-05-24 | 中国农业科学院兰州兽医研究所 | 一株牛皮肤成纤维永生化细胞系的建立方法及应用 |
| WO2024122579A1 (ja) * | 2022-12-06 | 2024-06-13 | 北山ラベス株式会社 | 不死化細胞の製造方法 |
| AU2023415203A1 (en) * | 2022-12-28 | 2025-08-07 | National University Corporation Chiba University | Method for regulating degree of cell differentiation |
| WO2025070651A1 (ja) * | 2023-09-29 | 2025-04-03 | 国立大学法人千葉大学 | 造血幹細胞及び造血前駆細胞の増殖を促進する方法。 |
| WO2025106446A1 (en) * | 2023-11-13 | 2025-05-22 | Memorial Sloan-Kettering Cancer Center | Monocyte or macrophage compositions with enhanced anti- tumor activity and uses thereof |
| CN119662736A (zh) * | 2024-12-16 | 2025-03-21 | 西南民族大学 | 一种牦牛肌内前体脂肪永生化细胞系及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE311466T1 (de) * | 1995-02-10 | 2005-12-15 | Univ California | Menschliche pancreas zellinien: entwicklungen und anwendungen |
| US6303289B1 (en) * | 1999-03-23 | 2001-10-16 | Elenor Roosevelt Institute | Composition and methods for the treatment of cancer and viral infections |
| GB0005856D0 (en) * | 2000-03-10 | 2000-05-03 | Reneuron Ltd | Genetic constructs |
| WO2003001198A1 (en) * | 2001-06-21 | 2003-01-03 | Regents Of The University Of California | Immortalization of human cells by the ectopic expression of human telomerase reverse transcriptase |
| GB0125773D0 (en) * | 2001-10-26 | 2001-12-19 | Reneuron Ltd | Constructs |
| GB0316882D0 (en) * | 2003-07-18 | 2003-08-20 | Consejo Superior Investigacion | Reversible immortalization of OEG from human olfactory bulbs as a tool to promote spinal cord regeneration |
| CN1590539A (zh) * | 2003-09-02 | 2005-03-09 | 中国人民解放军第四军医大学口腔医学院 | 一种使皮肤成纤维细胞永生化的方法 |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| EP1652932A1 (en) * | 2004-11-02 | 2006-05-03 | GBF Gesellschaft für Biotechnologische Forschung mbH | Method for the generation of virus producing cell lines and cell lines |
| US20100190250A1 (en) * | 2005-10-14 | 2010-07-29 | Jifan Hu | Methods of Rejuvenating Cells In Vitro and In Vivo |
| EP2141241A1 (en) * | 2008-07-03 | 2010-01-06 | Helmholtz-Zentrum für Infektionsforschung GmbH | Senescence cells and methods for its production |
| CN102105488A (zh) * | 2008-07-18 | 2011-06-22 | 朱志强 | 真核细胞的长期培养方法及其应用 |
| DK3257943T3 (da) * | 2010-11-02 | 2019-10-21 | Helmholtz Zentrum Infektionsforschung Gmbh | Fremgangsmåder og vektorer til celleimmortalisering |
-
2011
- 2011-11-02 DK DK17180843.9T patent/DK3257943T3/da active
- 2011-11-02 WO PCT/EP2011/005528 patent/WO2012059223A1/en not_active Ceased
- 2011-11-02 CN CN2011800523329A patent/CN103282498A/zh active Pending
- 2011-11-02 JP JP2013537037A patent/JP6147191B2/ja active Active
- 2011-11-02 CA CA2814704A patent/CA2814704C/en active Active
- 2011-11-02 EP EP17180843.9A patent/EP3257943B1/en active Active
- 2011-11-02 EP EP11778807.5A patent/EP2635682B1/en active Active
- 2011-11-02 US US13/882,709 patent/US9453203B2/en active Active
- 2011-11-02 AU AU2011325439A patent/AU2011325439B2/en not_active Ceased
-
2016
- 2016-01-08 JP JP2016002193A patent/JP2016165265A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2814704C (en) | 2020-04-07 |
| EP3257943A3 (en) | 2018-01-10 |
| WO2012059223A1 (en) | 2012-05-10 |
| EP3257943B1 (en) | 2019-09-11 |
| JP6147191B2 (ja) | 2017-06-14 |
| US9453203B2 (en) | 2016-09-27 |
| JP2016165265A (ja) | 2016-09-15 |
| US20130273550A1 (en) | 2013-10-17 |
| CA2814704A1 (en) | 2012-05-10 |
| AU2011325439A1 (en) | 2013-05-02 |
| CN103282498A (zh) | 2013-09-04 |
| JP2014503190A (ja) | 2014-02-13 |
| EP3257943A2 (en) | 2017-12-20 |
| EP2635682B1 (en) | 2017-07-19 |
| EP2635682A1 (en) | 2013-09-11 |
| AU2011325439B2 (en) | 2015-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3257943T3 (da) | Fremgangsmåder og vektorer til celleimmortalisering | |
| DK2638149T3 (da) | Immortalisering af epitelceller og fremgangsmåder til anvendelse | |
| DK3176128T3 (da) | Fremgangsmåde og system til lagring af hydrogen | |
| DK3290061T3 (da) | Fremgangsmåder og anordninger til cellulær transplantation | |
| DK3468197T3 (da) | Fremgangsmåde til interforudsigelse og indretning dertil | |
| DK3354665T3 (da) | Modificerede alginater til celleindkapsling og celleterapi | |
| DK2884999T4 (da) | Fremgangsmåde og sammensætninger til cellulær immunterapi | |
| DK2855667T3 (da) | Fremgangsmåder til manipulation af allogeniske og immunosuppressiv-resistante T-celler til immunterapi | |
| DK3078388T3 (da) | Tværbundne hydrogeler til blødvævsforøgelse | |
| DK3421051T3 (da) | Fremgangsmåder til glycokonjugering og sammensætninger | |
| DK2624567T3 (da) | Blokinddelingsfremgangsmåde og afkodningsindretning | |
| DK3578201T3 (da) | Fremgangsmåder og sammensætninger til naturlige dræberceller | |
| DK3622883T3 (da) | Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger | |
| DK2606003T3 (da) | Anordning, system og fremgangsmåde til fremstilling af hydrogen | |
| DK2785683T3 (da) | Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf | |
| DK2506416T3 (da) | System og fremgangsmåde til strømkonvertering | |
| DK2625253T3 (da) | System og fremgangsmåde til ristning af biomasse | |
| DK2649812T3 (da) | Høreapparat og en fremgangsmåde til at forbedre talegengivelse | |
| DK2361704T4 (da) | Metalmultifasemateriale og fremgangsmåde til fremstilling deraf | |
| DK2758655T3 (da) | Systemer og fremgangsmåder til forbedrede vandrotorer | |
| DK2705143T3 (da) | Protein-induceret pluripotent celleteknologi og anvendelse deraf | |
| DK2676139T3 (da) | Fremgangsmåde til diagnosticering af cancer og diagnosekit til måling af nk celle-aktivitet | |
| DK3967868T3 (da) | Væskeforstøver og fremgangsmåde | |
| DK2727647T3 (da) | Kemisk reaktionsapparat og kemisk reaktionsmetode | |
| DK2916881T3 (da) | Sulfaterede alginat hydrogeler til cellekultur og terapi |